The Efficacy and Safety of Injectable Prolonged-Release Buprenorphine (Buvidal) in Adults with Opioid Dependence: A Systematic Review and Meta-Analysis

Efficacy and Safety of Buvidal


  • Laura Williams Betsi Cadwaladr University Health Board, Wales, UK
  • Saima Saima Betsi Cadwaladr University Health Board, Wales, UK
  • Asha Dhandapani Betsi Cadwaladr University Health Board, Wales, UK
  • Opeyemi Ikuewumi Betsi Cadwaladr University Health Board, Wales, UK


systematic review, meta analysis, buvidal, buprenorphine, injectable buprenorphine, safety, efficacy, side effects


Background: The development of a long-acting buprenorphine injection may resolve issues of non-compliance, diversion, accidental overdose, and misuse in opiate dependency treatment. Our systematic review and meta-analysis examined safety and efficacy data for prolonged-release Buprenorphine injections.

Methods: Data sources: We searched Ovid, PubMed, Cochrane Library and Google Scholar from inception until 01/10/2022. Intervention was long-acting injectable buprenorphine compared to control including sublingual buprenorphine or placebo.   We included RCTs that reported on efficacy and safety outcomes in inpatients and outpatients over 18 years with opiate dependency. Primary outcome measure was treatment efficacy, using the markers negative urine drug screen results and treatment retention. Secondary outcomes focussed on side effects. Results: Among 10,202 articles, 111 were included for full-text reviews. Of the 111 articles, 6 were included in the final meta-analysis. There were a total of 1785 participants.

Results: Regarding treatment retention, Buvidal demonstrated a statistically significant increase compared to the control group (OR = 1.46, 95% CI = 1.12 to 1.89, P=0.005). Regarding negative urine samples, Buvidal again demonstrated a statistically significant increase in negative urine samples compared to the control group (OR = 1.38, 95% CI = 1.26 to 1.52, P < 0.00001). There were no statistically significant differences between the two groups in relation to the secondary outcome measures.

Conclusions: In our experience, this is the only systematic review and meta-analysis regarding efficacy and safety of Buvidal, and our results support its use as a treatment option for recovery of opiate users.


Frost M, Bailey GL, Lintzeris N, et al. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. Addiction (Abingdon, England). 2019;114(8):1416-1426. doi:

Svenaeus F. Diagnosing mental disorders and saving the normal: American Psychiatric Association, 2013. Diagnostic and statistical manual of mental disorders, American Psychiatric Publishing: Washington, DC. 991 pp., ISBN: 978-0890425558. Price: $122.70. Medicine, Health Care and Philosophy. 2014 May; 17:241-4.

Chang KC, Lee KY, Lu TH, Hwang JS, Lin CN, Ting SY, Chang CC, Wang JD. Opioid agonist treatment reduces losses in quality of life and quality-adjusted life expectancy in heroin users: Evidence from real world data. Drug and alcohol dependence. 2019 Aug 1; 201:197-204.

Nordeck CD, Welsh C, Schwartz RP, Mitchell SG, Cohen A, O’Grady KE, Gryczynski J. Rehospitalization and substance use disorder (SUD) treatment entry among patients seen by a hospital SUD consultation-liaison service. Drug and alcohol dependence. 2018 May 1; 186:23-8.

Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, Bruneau J, Altice FL, Henderson G, Rahimi-Movaghar A, Larney S. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet 2019; 394: 1560-1579.

Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet 2019; 393: 1760-1772.

Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies--tackling the opioid overdose epidemic. N Engl J Med 2014; 370: 2063-2066.

Gossop M, Marsden J, Stewart D, Treacy S. Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend 2001; 62: 255-264.

Bell J. Pharmacological maintenance treatments of opiate addiction. Br J Clin Pharmacol 2014; 77: 253-263.

Andorn AC, Haight BR, Shinde S, et al. Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis. Journal of Clinical Psychopharmacology. 2020;40(3):231-239.

NICE National Institute for Health and Care Excellence. Opioid dependence: buprenorphine prolonged-release injection (Buvidal) [Internet]. 2019 [cited 23 October 2023]. Available from: Opioid dependence: buprenorphine prolonged-release injection (Buvidal) (

Haight BR, Learned SM, Laffont CM, et al. Efficacy and Safety of a Monthly Buprenorphine Depot Injection for Opioid Use Disorder: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial. SSRN Electronic Journal. Published online 2018.

Sigmon SC, Wong CJ, Chausmer AL, Liebson IA, Bigelow GE. Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Addiction. 2004;99(11):1439-1449.

Lintzeris N, Dunlop AJ, Haber PS, et al. Patient-Reported Outcomes of Treatment of Opioid Dependence with Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine. JAMA Network Open. 2021;4(5): e219041.

Lee JD, Malone M, McDonald R, et al. Comparison of Treatment Retention of Adults with Opioid Addiction Managed with Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release from Jail. JAMA Network Open. 2021;4(9): e2123032.

Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine with Naloxone for Treatment of Opioid Use Disorder. JAMA Internal Medicine. 2018;178(6):764.

Soyka M. Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update. Pharmacopsychiatry 2021; 54: 18-22.

Allikmets S, Vink JP. Clinical applications of buprenorphine depot injection for opioid use disorder. Addiction 2020; 115: 190.

Schulte B, Lehmann K, Schmidt CS, Rühling E, Weber B, Schäfer I, Reimer J, Verthein U. Addiction Recovery Among Opioid-Dependent Patients Treated With Injectable Subcutaneous Depot Buprenorphine: Study Protocol of a Non-randomized Prospective Observational Study (ARIDE). Front Psychiatry 2020; 11: 580863.

Larance B, Byrne M, Lintzeris N, Nielsen S, Grebely J, Degenhardt L, Shahbazi J, Shanahan M, Lancaster K, Dore G, Ali R, Farrell M; CoLAB study team. Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study. BMJ Open 2020; 10: e034389.

Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. Journal of addiction medicine. 2019 Mar;13(2):93.






Systematic Review and Meta-Analyses